Iterum Therapeutics Plc Stock Price Prediction
| ITRM Stock | USD 1.99 0.18 9.94% |
Oversold Vs Overbought
56
Oversold | Overbought |
EPS Estimate Next Quarter (0.24) | EPS Estimate Current Year (1.03) | EPS Estimate Next Year (0.82) | Wall Street Target Price 7.5 | EPS Estimate Current Quarter (0.21) |
Using Iterum Therapeutics hype-based prediction, you can estimate the value of Iterum Therapeutics PLC from the perspective of Iterum Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Iterum Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Iterum because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Iterum Therapeutics after-hype prediction price | USD 2.59 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Iterum |
Iterum Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Iterum Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Iterum Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Iterum Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Iterum Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Iterum Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Iterum Therapeutics' historical news coverage. Iterum Therapeutics' after-hype downside and upside margins for the prediction period are 0.13 and 12.19, respectively. We have considered Iterum Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Iterum Therapeutics is abnormally volatile at this time. Analysis and calculation of next after-hype price of Iterum Therapeutics PLC is based on 3 months time horizon.
Iterum Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Iterum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iterum Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Iterum Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.14 | 9.60 | 0.79 | 0.01 | 9 Events / Month | 13 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.99 | 2.77 | 39.05 |
|
Iterum Therapeutics Hype Timeline
Iterum Therapeutics PLC is currently traded for 1.99. The entity has historical hype elasticity of 0.79, and average elasticity to hype of competition of -0.01. Iterum is projected to increase in value after the next headline, with the price projected to jump to 2.767 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 39.05%, whereas the daily expected return is currently at 1.14%. The volatility of related hype on Iterum Therapeutics is about 155076.92%, with the expected price after the next announcement by competition of 1.98. Iterum Therapeutics PLC currently holds 18.96 M in liabilities with Debt to Equity (D/E) ratio of 0.58, which is about average as compared to similar companies. Iterum Therapeutics PLC has a current ratio of 9.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Iterum Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next projected press release will be in about 9 days. Check out Iterum Therapeutics Basic Forecasting Models to cross-verify your projections.Iterum Therapeutics Related Hype Analysis
Having access to credible news sources related to Iterum Therapeutics' direct competition is more important than ever and may enhance your ability to predict Iterum Therapeutics' future price movements. Getting to know how Iterum Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Iterum Therapeutics may potentially react to the hype associated with one of its peers.
Iterum Therapeutics Additional Predictive Modules
Most predictive techniques to examine Iterum price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Iterum using various technical indicators. When you analyze Iterum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Iterum Therapeutics Predictive Indicators
The successful prediction of Iterum Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Iterum Therapeutics PLC, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Iterum Therapeutics based on analysis of Iterum Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Iterum Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Iterum Therapeutics's related companies. | 2023 | 2024 (projected) | Graham Number | 5.74 | 5.45 | Receivables Turnover | 0.0385 | 0.0366 |
Story Coverage note for Iterum Therapeutics
The number of cover stories for Iterum Therapeutics depends on current market conditions and Iterum Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Iterum Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Iterum Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Iterum Therapeutics Short Properties
Iterum Therapeutics' future price predictability will typically decrease when Iterum Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Iterum Therapeutics PLC often depends not only on the future outlook of the potential Iterum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Iterum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13 M | |
| Cash And Short Term Investments | 23.9 M |
Check out Iterum Therapeutics Basic Forecasting Models to cross-verify your projections. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.